Nephrocare Health Services marked its entry into the Indian stock market on December 17, 2025, with a positive opening, following solid demand during its initial public offering. The company’s shares were listed at ₹490 per share on the National Stock Exchange, reflecting a premium of 6.5% over the issue price of ₹460. On the Bombay Stock Exchange, the stock opened slightly higher at ₹491.70, translating into a gain of 6.89% from the IPO price.
While the listing began on an encouraging note, the stock later pared some of its early gains during the trading session. On the BSE, the share price eased from an intraday high of ₹498.70 to a low of ₹475, placing it around 3.2% above the issue price at its weakest point of the day.
IPO Subscription and Investor Response
The Nephrocare Health IPO received a robust response from investors across categories during the three-day bidding period between December 10 and December 12. By the close of subscriptions, the issue was subscribed to 13.96 times overall.
Qualified institutional buyers led the demand, subscribing to their portion 27.47 times. Non-institutional investors followed closely with a subscription of 24.27 times, while the retail segment was subscribed to 2.31 times. In total, bids were placed for over 18.68 crore shares against approximately 1.34 crore shares on offer, highlighting broad-based interest in the offering.
IPO Structure and Key Details
Nephrocare Health’s IPO was a book-built issue aimed at raising nearly ₹871 crore. The offering comprised a fresh issue of 7.7 million equity shares amounting to ₹353.75 crore, along with an offer for sale of 11.3 million shares valued at ₹517.64 crore.
The price band for the IPO was fixed between ₹438 and ₹460 per share, with a lot size of 32 shares. At the upper end of the band, the minimum retail investment worked out to ₹14,720. The allotment of shares was finalised on December 15, ahead of the company’s listing on the exchanges.
Use of IPO Proceeds
As outlined in the red herring prospectus, Nephrocare Health will not receive any proceeds from the offer for sale component, as those funds will be distributed to the selling shareholders. The net proceeds from the fresh issue are planned to be utilised towards capital expenditure for setting up new dialysis clinics across India.
In addition, a portion of the funds will be allocated for the repayment or prepayment of certain borrowings, along with meeting general corporate requirements to support ongoing operations and expansion plans.
About Nephrocare Health
Nephrocare Health is an Indian dialysis and renal care services provider that has expanded its footprint primarily across Tier 2 and Tier 3 cities. The company operates through an asset-light model, supported by strategic partnerships, allowing it to scale efficiently across domestic markets and select international locations.
Its focus on accessible renal care services has enabled Nephrocare Health to build a growing network of clinics catering to patients requiring long-term dialysis and kidney-related treatments.
People Also Read:
- Park Medi World IPO Opens Below Issue Price, Listing at About 4% Discount
- Corona Remedies IPO Delivers a Strong Market Debut with 38% Listing Premium
- Aequs IPO: Shares Begin Trade with Nearly 13% Listing Premium
- Vidya Wires IPO: Shares List Flat at ₹52 in a Muted Market Debut
- Meesho IPO: Stellar Market Debut as Stock Lists Nearly 46% Above Issue Price
Conclusion
Nephrocare Health’s IPO listing reflects a measured yet positive market response, supported by strong institutional participation and healthy overall subscription levels. While the stock saw some volatility after listing, its debut at a premium underscores investor interest in the company’s business model and growth strategy within the healthcare services segment.
As the stock settles into post-listing trade, market participants will continue to track its performance against broader sector trends and execution milestones.
If you are exploring more investment opportunities, check out our dedicated page on upcoming IPO listings to stay updated on the latest market offerings.
